diseasecwd
human
prion
vcjd
vcjd
coxiella
burnetiith
agent
q
fever
dengu
virus
hav
hev
japanes
encephalitisj
complex
tickborn
enceph
virusestbev
human
parvoviru
also
tabl
releas
outlin
pathogen
reduct
clinic
trialsresult
publish
availabilitycommerci
routin
use
technolog
countri
necess
list
eid
agent
never
complet
due
natur
emerg
recogn
system
assess
riskthreat
eid
potenti
impact
blood
safeti
avail
must
includ
process
monitor
identifi
evalu
estim
sever
assess
risk
develop
intervent
thu
toolkit
contain
necessari
tool
eid
monitor
horizon
scan
validationeffect
evalu
intervent
develop
goal
develop
systemat
approach
risk
assess
intervent
develop
impact
emerg
infecti
upon
blood
safeti
intend
educ
provid
advis
risksintervent
timelyaccur
fashion
recognit
newli
describ
infecti
diseas
agent
continu
place
demand
collector
blood
worldwid
ensur
safeti
approach
need
ensur
mechan
place
allow
surveil
threat
assess
trigger
action
need
intervent
develop
implement
assess
efficaci
agent
concern
divers
natur
emerg
unpredict
exampl
agent
intern
recogn
potenti
exist
threat
blood
safeti
includ
newli
describ
middl
east
respiratori
syndrom
coronaviru
merscov
dengu
virus
chikungunya
viru
hepat
e
viru
hev
august
group
aabb
unit
state
publish
supplement
transfus
review
definit
background
eid
agent
pose
real
theoret
threat
transfus
safeti
exist
effect
intervent
lack
definit
includ
recognit
new
agent
previous
undetect
agent
diseas
infecti
origin
lastli
reemerg
known
infect
declin
incid
one
estim
rate
emerg
includ
new
virus
discov
everi
year
anim
origin
infect
human
case
exposur
one
sever
rout
occur
predict
rate
emerg
continu
well
beyond
year
human
exposur
occur
number
overlap
condit
mani
human
clearli
precipit
forc
new
agent
mutat
speci
jump
failur
prior
control
measur
popul
growth
movement
transport
behaviour
chang
sanitari
dietari
war
intens
farm
practic
name
addit
eid
agent
zoonot
origin
repres
divers
group
agent
infect
multipl
transmiss
rout
may
result
acut
chronic
infect
deriv
human
activ
importantli
emerg
unpredict
necessari
attribut
transfus
transmiss
includ
follow
presenc
agent
blood
asymptomat
phase
donor
agent
survivalpersist
blood
processingstorag
lastli
agent
must
recogn
respons
clinic
appar
outcom
least
proport
recipi
becom
infect
respons
respect
blood
safeti
approach
eid
agent
vari
relat
sever
agent
incid
preval
rate
emerg
origin
aabb
group
identifi
eid
agent
concern
blood
safeti
agent
enough
evidencelikelihood
transfus
transmiss
eg
blood
phase
potenti
clinic
diseas
warrant
consider
supplement
fact
sheet
publish
provid
inform
follow
agent
classif
background
diseas
agent
import
clinic
syndromesdiseas
caus
transmiss
mode
includ
vectorsreservoir
likelihood
transfus
transmiss
proven
transfus
transmit
inform
known
case
feasibl
predict
success
intervent
could
use
donor
screen
question
test
avail
diagnost
could
adapt
donat
screen
final
efficaci
known
inactiv
method
plasmaderiv
product
supplement
also
includ
separ
section
pathogen
reduct
technolog
blood
compon
use
publish
data
agent
priorit
rel
scientificepidemiolog
threat
well
perceiv
threat
commun
includ
concern
express
regul
blood
agent
given
highest
prioriti
due
known
transfusiontransmiss
threat
severefat
diseas
recipi
vcjd
prion
dengu
virus
oblig
redcel
parasit
caus
babesiosi
b
microti
relat
babesia
although
focu
supplement
unit
state
canada
mani
agent
process
applic
worldwid
expert
priorit
agent
differ
depend
local
need
prioriti
given
west
nile
viru
dengu
virus
leishmania
chikungunya
viru
agent
malaria
lyme
diseas
tickborn
enceph
viru
note
sever
agent
includ
agent
lyme
diseas
never
document
transfusiontransmit
sinc
public
supplement
six
new
fact
sheet
releas
yellow
fever
virus
includ
vaccin
breakthrough
infect
miscellan
arbovirus
xmrv
includ
comprehens
tabl
publish
literatur
human
parvovirus
bocavirus
measl
due
local
us
outbreak
also
exist
fact
sheet
updat
human
prion
vcjd
chronic
wast
diseas
prion
vcjd
prion
bartonella
coxiella
burnetii
agent
q
fever
result
massiv
outbreak
netherland
precipit
highintens
goat
farm
hev
due
increas
report
rnaposit
blood
donor
japan
europ
note
netherland
increas
number
precipit
highintens
pig
farm
japanes
enceph
je
complex
tickborn
enceph
virus
tbev
dengu
virus
three
transfusiontransmiss
cluster
one
report
hong
kong
singapor
puerto
rico
human
parvoviru
hepat
viru
hav
due
larg
multist
outbreak
us
anaplasma
phagocytophilum
eight
transfus
transmiss
report
us
erhlichia
includ
first
report
transfus
transmiss
us
b
microti
data
report
research
test
intervent
us
addit
tabl
releas
outlin
pathogen
reduct
clinic
trial
publish
result
avail
commerci
routin
use
technolog
countri
platelet
plasma
red
cell
whole
blood
necess
list
eid
agent
never
complet
due
natur
emerg
recogn
system
assess
risk
threat
eid
potenti
impact
blood
safeti
avail
must
includ
process
monitor
identifi
evalu
estim
diseas
sever
assess
risk
develop
intervent
thu
aabb
eid
group
develop
toolkit
contain
necessari
tool
start
link
eid
monitor
site
horizon
scan
risk
assess
tool
flow
diagram
follow
one
proce
determin
whether
intervent
develop
implement
requir
method
valid
assess
efficaci
introduc
intervent
goal
develop
systemat
approach
risk
assess
intervent
develop
impact
emerg
infect
upon
blood
safeti
intend
educ
advis
blood
system
time
accur
fashion
develop
toolkit
may
adapt
need
isbt
member
lesson
learn
aabb
exercis
countri
region
world
need
decid
prioriti
list
infecti
agent
may
repres
threat
transfus
recipi
well
process
surveil
action
agent
pose
immedi
safeti
threat
countri
especi
develop
world
eid
agent
origin
past
china
subsaharan
africa
tropic
central
south
america
may
also
choos
establish
epidemiologicmolecular
surveil
laboratori
collabor
exist
laboratori
enabl
rapid
agent
identif
diseas
character
exampl
agent
intern
recogn
potenti
exist
threat
blood
safeti
includ
merscov
dengu
virus
chikungunya
viru
hev
briefli
review
merscov
agent
betacoronaviru
first
describ
septemb
patient
saudi
arabia
relat
sever
acut
respiratori
syndrom
coronaviru
sar
result
infect
countri
includ
macau
hong
kong
fatal
rate
case
sar
bat
confirm
natur
reservoir
although
introduct
agent
human
like
contact
anim
mask
palm
civet
held
southern
chines
market
diseas
first
recogn
nov
middl
east
respiratori
syndrom
coronaviru
also
like
repres
zoonot
agent
infect
human
via
viral
adapt
speci
jump
intermedi
host
bat
suspect
ultim
reservoir
camel
infect
like
link
human
infect
theori
present
unproven
major
case
associ
sever
diseas
lower
respiratori
tract
result
pneumonia
multiorgan
failur
suscept
clinic
diseas
death
preexist
comorbid
chronic
condit
report
clinic
case
includ
diabet
hypertens
heart
diseas
kidney
diseas
unclear
whether
person
specif
condit
disproportion
infect
sever
diseas
novemb
report
us
center
diseas
control
prevent
cdc
world
health
organ
ten
countri
report
clinic
case
death
case
transmiss
associ
arabian
peninsula
vast
major
case
death
occur
travel
infect
patient
limit
persontoperson
transmiss
respons
case
report
elsewher
although
appear
limit
persontoperson
transmiss
cluster
case
describ
cluster
human
case
occur
associ
four
hospit
eastern
saudi
arabia
ultim
sourc
one
communityacquir
case
updat
merscov
rapid
risk
assess
routin
publish
european
centr
diseas
control
ecdc
regard
action
respect
blood
safeti
care
surveil
requir
risk
involv
merscov
rapidli
evolv
present
date
one
studi
report
test
blood
donor
includ
saudi
arabia
nonreact
merscov
neutral
antibodi
evid
transfus
transmiss
dengu
virus
includ
four
genet
relat
virus
genet
homolog
four
classifi
arbovirus
arthropodborn
virus
arbovirus
involv
replic
arthropod
host
usual
mosquito
tick
worldwid
distribut
respons
huge
period
epidem
dengu
virus
famili
flavivirida
along
relat
virus
west
nile
viru
yellow
fever
viru
relat
virus
arbovirus
also
includ
hundr
agent
mani
human
pathogen
viral
famili
bunyavirida
togavirida
includ
alphaviru
chikungunya
describ
dengu
virus
import
agent
due
number
human
infect
clinic
diseas
associ
death
ongo
expans
worldwid
estim
greater
countri
endem
tropic
subtrop
billion
peopl
risk
imposs
know
number
clinic
case
actual
occur
year
one
estim
global
burden
dengu
worldwid
pandem
million
infect
across
four
contin
million
symptomat
includ
case
sever
dengu
asia
latin
america
dengu
lead
caus
hospit
children
sinc
effect
vaccin
specif
treatment
vector
control
intervent
dengu
cycl
involv
human
mosquito
primarili
aegypti
sylvat
cycl
also
occur
recent
investig
associ
preliminari
report
new
dengu
viru
type
immun
given
viral
type
consid
lifelong
due
incomplet
antibodi
neutral
type
secondari
infect
differ
type
lead
sever
diseas
refer
sever
dengu
includ
haemorrhag
fever
andor
shock
major
clinic
case
classifi
fever
defin
fever
plu
two
symptom
commonli
includ
chill
pain
eye
bodi
ach
sever
breakbon
fever
rash
easili
bruis
evid
haemorrhag
condit
three
transfusiontransmiss
cluster
report
first
hong
kong
anoth
singapor
two
clinic
case
one
antibodi
seroconvers
document
lastli
case
transfusiontransmit
haemorrhag
fever
puerto
rico
infect
individu
may
donat
blood
sinc
estim
dengueinfect
asymptomat
even
individu
develop
symptom
day
asymptomat
period
puerto
rico
island
caribbean
us
territori
experi
annual
outbreak
research
blood
donat
screen
puerto
rico
document
rate
dengu
rna
blood
donor
outbreak
year
estim
number
virem
donat
risk
dengu
transfus
transmiss
model
cdc
result
model
output
observ
number
rnaposit
donor
blood
donat
screen
show
trend
although
routin
screen
american
red
cross
occur
puerto
rico
clinic
efficaci
intervent
unknown
sinc
number
transfus
transmiss
document
unclear
number
transfus
transmiss
higher
endem
area
consid
magnitud
dengu
outbreak
high
viral
load
associ
infect
donor
possibl
theori
includ
absenc
effect
hemovigil
mani
countri
impact
dengu
inabl
differenti
mosquito
versu
transfus
transmiss
protect
secondari
infect
due
heterolog
antibodi
present
transfus
unit
immunosuppress
mani
recipi
possibl
differ
clinic
outcom
depend
rout
infect
ie
mosquito
versu
transfus
anoth
flaviviru
chikungunya
viru
endem
mani
tropic
area
dengu
frequent
present
similar
symptom
epidem
period
sever
bodi
ach
especi
joint
pain
crippl
arthriti
dengu
name
chikungunya
refer
inabl
straighten
due
intens
pain
bend
makon
languag
explos
outbreak
occur
reunion
island
island
southwest
indian
ocean
east
africa
late
begin
outbreak
clinic
case
reunion
island
document
effect
popul
infect
exhibit
symptom
anoth
million
case
outbreak
india
increas
sever
extent
outbreak
believ
due
mutat
affect
viral
envelop
protein
allow
replic
altern
mosquito
vector
albopictu
result
increas
viral
load
greater
virul
compar
replic
primari
mosquito
vector
egypti
transfusiontransmit
risk
model
estim
risk
per
donat
howev
transfus
transmiss
never
document
notabl
island
french
coloni
number
intervent
put
place
prevent
theoret
transfus
transmiss
includ
suspens
blood
collect
area
risk
estim
higher
risk
hepat
b
viru
transfus
transmiss
implement
platelet
pathogen
inactiv
chikungunya
viru
rna
nucleic
acid
test
continent
franc
deferr
live
travel
endem
area
subsequ
outbreak
northern
itali
occur
involv
approxim
case
viral
introduct
believ
clinic
case
individu
return
india
consequ
spread
local
via
albopictu
data
outbreak
use
valid
risk
assess
tool
develop
provid
quantit
transmiss
estim
eid
risk
blood
transfus
output
model
base
outbreak
peak
estim
preval
per
donor
lead
infecti
donat
infecti
blood
compon
sever
outcom
recipi
base
assum
infect
individu
develop
sever
diseas
subsequ
casecontrol
studi
chikungunya
outbreak
thailand
investig
develop
symptom
viremia
laboratoryconfirm
posit
n
asymptomat
control
rna
posit
seroconvert
median
viral
load
pfuml
rang
pfuml
versu
n
classifi
symptomat
case
viremia
fewer
day
rna
posit
fewer
day
symptomat
individu
median
viral
load
pfuml
rang
pfuml
p
vs
control
hepat
e
viru
singlestrand
rnacontain
small
nonenvelop
viru
genu
hepesviru
one
serotyp
four
genotyp
differ
geograph
distribut
epidemiolog
clinic
featur
hepat
e
viru
global
common
caus
acut
hepat
estim
million
incid
infect
per
year
million
acut
case
death
per
year
genotyp
commonli
associ
larg
explos
waterborn
outbreak
along
foodborn
outbreak
similar
hav
genotyp
also
associ
overal
higher
rate
acut
diseas
unknown
reason
increas
sever
pregnant
women
mortal
especi
third
trimest
contrast
genotyp
occur
human
commonli
swine
sever
anim
thu
infect
genotyp
occur
transmiss
food
notabl
via
raw
undercook
pork
product
contain
liver
andor
blood
gener
less
virul
either
genotyp
genotyp
infect
result
sever
diseas
immunosuppress
individu
notabl
solid
organ
transplant
sot
recipi
lead
chronic
infect
cirrhosi
sever
liver
diseas
becom
chronic
infect
sot
recipi
investig
hev
rna
netherland
posit
hevrnaposit
patient
develop
cirrhosi
antibodi
preval
blood
donor
vari
greatli
depend
geograph
locat
test
use
reproduc
seen
increas
age
unrel
cohort
effect
like
result
increas
preval
time
rna
genotyp
recov
dutch
blood
donor
rate
high
sequenc
close
relat
patient
pig
area
studi
igg
antibodi
preval
igm
increas
preval
age
intens
pig
farm
netherland
exampl
may
amplifi
viru
spread
via
contamin
meat
contamin
water
use
irrig
even
higher
igg
seropreval
rate
document
southwest
franc
link
consumpt
local
produc
pork
product
contain
undercook
pork
anoth
studi
blood
donor
us
preval
igg
ci
igm
donor
circul
rna
donor
collect
vs
remaind
preval
p
vs
preval
rang
year
old
year
old
part
studi
donorrecipientlink
repositori
test
two
suspect
case
hev
transfus
transmiss
investig
neither
could
confirm
one
case
passiv
antibodi
rna
transfus
patient
die
prior
determin
infect
transfus
hev
rna
rnaposit
donor
studi
case
one
level
igg
pretransfus
assay
cutoff
posttransfus
assay
cutoff
sinc
antibodi
evolut
indic
recent
seroconvers
recipi
like
infect
prior
transfus
sinc
least
transfus
transmiss
document
worldwid
includ
case
japan
uk
franc
saudi
arabia
taiwan
india
hev
nonenvelop
resist
inactiv
thu
solventdeterg
plasma
manufactur
screen
plasma
donor
andor
pool
reduc
hev
rna
concentr
ie
octapla
us
commerci
test
develop
screen
plasma
hev
rna
blood
system
must
consid
prepar
unknown
includ
trigger
action
develop
intervent
respect
safeti
blood
eid
agent
exampl
review
repres
wide
varieti
agent
divers
characterist
epidemiolog
transmiss
rout
differ
risk
lead
differ
consider
introduct
intervent
toolkit
develop
process
final
product
includ
method
monitor
eid
agent
emerg
identifi
recogn
transfusiontransmiss
threat
quantifi
risk
appropri
reduc
associ
risk
transfus
recipi
consid
implement
blood
system
author
declar
conflict
interest
